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ABSTRACT
This study aims to provide current insights into practice variation among genetic
counselors (GC’s) and medical examiners (ME’s) with regards to post-mortem genetic testing in
the context of Sudden Cardiac Death (SCD). Ninety total respondents (37 GC’s, 47 ME’s, 3
cardiologists, and 3 forensic pathologists) were surveyed, with questions addressing: who
initiates testing and for what indications; what types of tests are ordered and how are they paid
for; and what areas of the post-mortem genetic testing process need to be addressed in future
studies for potential improvement. Significantly more GC’s ordered post-mortem genetic testing
for SCDs than ME’s, with financial constraints being the main obstacle for ME’s and sample
type/amount being the main determining factor for GC’s. The majority of respondents who
ordered testing used arrhythmia panels with both cardiomyopathies and channelopathies. Most
GC’s (64.9%) reported families paying out-of-pocket, whereas many ME’s (48.9%) reported
their ME Office covering testing costs. Experience with insurance coverage was highly varied
across GC’s, while ME’s were generally unsure about coverage. Seventeen ME’s (36.2%)
reported no provision of pre-test counseling to families affected by SCD; 14 (29.8%) reported
referring families to other providers or research organizations for determination of testing. When
cost was not a barrier, grief was reported to be the greatest obstacle to testing. Overall, there
were notable differences in practice, knowledge, and opinions between GC’s and ME’s with
regards to pre-test counseling, financial responsibility, and key determining factors for testing,
respectively. Future research is needed to help establish a uniform and enforceable protocol that
healthcare professionals (including ME’s) and insurance companies can adhere to for postmortem genetic testing in SCD cases, so that all affected families may receive the same standard
of care during one of their most difficult times.
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INTRODUCTION
Sudden unexplained death (SUD) describes any death that occurs as a natural and fatal
event within an hour of symptoms onset, or within 24 hours after the affected individual was
witnessed as completely healthy (Adabag, Luepker, Roger, & Gersh, 2010; Lim, Gibbs, Potts, &
Sanatani, 2010; Srinivasan & Schilling, 2018). In some SUD cases, a completed autopsy can
determine no identifiable cause or can suggest a potential genetic cause of death (Middleton et
al.,2013). Sudden cardiac death (SCD), by comparison, refers specifically to a subset of SUDs
with a definitive cardiovascular cause, or can be applied to any death or cardiac arrest that occurs
outside of the hospital or in the emergency room, presumably due to coronary/ischemic heart
disease (Adabag et al., 2010; Hayashi, Shimizu, & Albert, 2015).
Worldwide SCD accounts for 15-20% of all deaths, and over 60% of all deaths from
cardiovascular disease (Adabag et al., 2010; Hayashi et al., 2015). In the U.S., a 2018 report
from the American Heart Association cited SCD prevalence in the U.S. as 13.5%, or 1 in every
7.4 people (Benjamin et al., 2018). Risk factors for SCD can include certain behaviors (poor
eating, heavy alcohol use), sex, age, ethnicity (African-American or non-Asian), past medical
history (hypertension, diabetes), family history of SCD, and specific genetic variants (Wong et
al., 2019). The majority of SCDs (75%) are caused by coronary heart disease (CHD) (also called
coronary artery disease and ischemic heart disease), followed by cardiomyopathies (15%),
valvular heart disease (5%), inherited arrhythmia syndromes (2%), and other causes (3%)
(Srinivasan & Schilling, 2018).
The prevalence of arrhythmias ranges from 1/1,000 to 1/10,000, and 1/250 to 1/1,000 for
cardiomyopathies (Lin et al., 2017). Primary arrhythmic disorders (long-QT syndrome, Brugada
syndrome, and catecholaminergic polymorphous ventricular tachycardia) are defined as
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conditions where improper functioning of ion channel proteins in the heart muscle cells causes
irregular heartbeats. On the other hand, cardiomyopathies (hypertrophic cardiomyopathy, dilated
cardiomyopathy, and arrhythmogenic cardiomyopathy) are a heterogeneous group of diseases
affecting the structure and/or function of the heart muscle. Both channelopathies and
cardiomyopathies can be inherited or acquired (some cardiomyopathies can also be idiopathic),
and both can have sudden death presenting as the first symptom.
Many experts have emphasized the importance of post-mortem genetic testing for SCD
cases that are categorized as autopsy-negative, and recommend including it as a required
component for adequate postmortem assessment of SCD (Semsarian & Hamilton, 2012; Gollob
et al., 2011; Tester et al., 2012). The purpose of postmortem genetic testing is to identify whether
the deceased carried a pathogenic variant that explains their SCD, and to initiate genetic testing
in family members of the deceased (symptomatic or not) whenever a pathogenic variant is
detected, as they may also carry the variant and be at increased risk for SCD. Knowing the
specific causative variant(s) can allow for risk stratification and phenotype prediction in carriers.
This is useful because most cardiomyopathies and inherited arrhythmias have variable
expressivity and low penetrance (Bezzina, Lahrouchi & Priori, 2015). Besides providing
genotype-phenotype correlations, genetic test results can also highlight suitable treatments,
medications, and enhanced screening options for eligible individuals. For example, some
individuals with a specific variant have an optimal response to beta blockers, while those with
other variants experience symptom recurrences despite full-dose beta blockers. In the future,
individuals diagnosed with HCM who carry a specific SNP that can be targeted by an adeno
associated virus-9-mediated RNAi may be eligible for gene therapy, which will suppress the
expression of the mutant allele of the gene (Bezzina, Lahrouchi & Priori, 2015).
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Overall, pathogenic variants found in this context are actionable, and positive result
disclosure necessitates the following discussion points: receiving follow-up, surveillance,
making lifestyle changes, taking medications, and even having cardioverter defibrillators
implanted for prophylaxis (especially if they are adults). All of these interventions can provide
patients with a normal life expectancy (Ackerman et al., 2016; Garcia-Elias & Benito, 2018;
Jacoby & McKenna, 2012; Miles et al., 2019; Tan et al., 2005).
Major genetic testing companies now offer next generation sequencing (NGS) panels that
encompass a great majority of the genes associated with arrhythmias, cardiomyopathies, or both.
These large panels have both advantages and disadvantages relative to more targeted testing. On
the one hand, the scale of such testing increases the yield of positive results. Tan et al. (2005)
used molecular genetic testing on 43 families and reported 8.9 asymptomatic carriers of inherited
disease per family. However, larger panels open the door for an increase in variants of unknown
significance (VUS). Additionally, larger panels expand to include genes with weaker
associations that may be influenced by modifier genes or environmental factors, further
complicating variant interpretations (Kapplinger et al., 2011). These genes may have small or
uncertain clinical utility. The need for lengthy counseling, the emotional and psychological stress
associated with uncertainty, and the risk of misinterpretation by healthcare providers are all
challenges to the usage of large panels. Despite these disadvantages, the ease and coverage of
large diagnostic panels is often more appealing to providers.
To date, the ability to conduct post-mortem genetic testing has been limited due to the
absence of resources and insurance coverage. Lack of resources is a potential explanation for
why post-mortem genetic testing is not standard practice at most medical examiners’ offices. A
body is brought to a medical examiner’s attention under any of the following circumstances:
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death by criminal violence, by accident, by suicide, suddenly and when in apparent health, when
unattended by a physician, in a correctional facility, or in any suspicious or unusual manner. The
role of a medical examiner includes the following responsibilities: investigate the circumstances
surrounding the deaths, perform an autopsy and external examination, order or complete needed
lab tests and review results, determine cause and manner of death, complete death certificate, and
compile all findings into a report. In a 2013 position paper, the National Association of Medical
Examiners (NAME) presented recommendations for medical examiners to follow when retaining
postmortem samples for genetic testing in the context of sudden unexpected death (Owen et al.,
2013; Semsarian & Hamilton, 2012). The level of care outlined in this position paper is hard to
ensure, given that the infrastructure and funding systems of Medical Examiner Offices vary from
state to state, and feasibility of sample collection, storage, transport, and communication for each
location may differ. (Tester et al., 2012)
Besides limited resources, who or what institution is responsible for covering the cost of
post-mortem genetic testing is another area with inconsistencies. In a study by Mohammed et al.
(2017), 54% of individuals with a diagnosis applied for insurance, and 60% of them reported
being denied coverage on the basis of “sudden arrhythmia death syndromes” (SADS) as a preexisting condition. The authors addressed that these changes in coverage and premium rates
predated the full enforcement of protective provisions in the Affordable Care Act of 2010; they
anticipated that such forms of discrimination would be reduced after January 1, 2014, when the
provisions came into full effect. The Heart and Rhythm Society created a poster at the 2014
conference titled Review of Postmortem Clinical Genetic Testing Sample Success Rates and
Payors from Commercial Labs, which can now be found to the National Society of Genetic
Counselors (NSG) website. Out of the 313 postmortem cases surveyed, the majority were self-
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pay (42%), but other payor types included medical examiner and/or forensic pathologist (14%),
Canadian Ministries of Health and Pathology Services (24%), US medical Institution (11%),
commercial insurance (6%), and other (3%). There have been virtually no studies on insurance
coverage of genetic testing for postmortem analysis of suspected SCD, or for testing of family
members of victims with suspected SCD. Studies are needed to assess current postmortem
practices for sudden death, which may provide insight for outlining detailed and feasible sitespecific protocols.
For family members concerned about the financial burden of pursuing post-mortem
genetic testing (especially in light of its diagnostic uncertainty), alternative options have been
explored. An example is DNA banking, which may be more affordable and would allow families
to pursue testing at a later point when scientific knowledge in this area has advanced (Middleton
et al., 2013). Another option is using commercially available genetic testing services that provide
cardiac panels targeting genes associated with sudden death in those under age 40 (Methner et
al., 2016); these still involve an out-of-pocket expense, but may be less expensive (Tester et al.,
2012). Finally, another option discussed by Tester et al. (2012) is enrolling the deceased’s
sample into research-based genetic testing; here, the price is free, but the process can be
painfully slow. At this point in time, there is a shortage of available literature on current genetic
testing trends in the context of sudden cardiac death. This study surveys healthcare professionals
(medical examiners, genetic counselors, and cardiologists) who are involved in ordering postmortem genetic testing, to gain insight into their opinions on the following: who is ordering post
mortem testing, what specific tests are being ordered, what specific medical events necessitate
postmortem testing, and how coverage for postmortem testing varies by region.
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METHODS
This study was designed to capture the experience and perspective of medical providers
likely to have interacted with families following SCD, including GC’s, ME’s, and cardiologists.
Much of this study borrows from and expands upon Liu et al.’s (2018) exploration on genetic
counselors’ approach to postmortem genetic testing after sudden death. GC’s were recruited via
an email list of full members maintained by the National Society of Genetic Counselors (NSGC),
a professional organization for GC’s and other healthcare professionals involved in genetic
counseling. To recruit ME’s, the survey was sent to the National Association of Medical
Examiners (NAME) and to the International Association of Coroners and Medical Examiners
(IACME). Attempts at recruiting cardiologists were largely unsuccessful, although the survey
was distributed to colleagues by several cardiologists reached through personal contacts. For
NSGC, NAME, and IACME, a total of two emails were sent by each organization—one initial
email, and one reminder email.
A survey was developed, evaluated by our advisors, and piloted by one cardiologist
before being distributed using surveymonkey.com (a pilot was not conducted with GC’s or ME’s
due to time constraints). The introduction to the survey included informed consent and specified
inclusion criteria limiting participation to individuals directly or indirectly involved with
postmortem genetic testing for cases of sudden cardiac death (SCD). The survey consisted of a
maximum of 27 questions and utilized skip logic. All responses were anonymous. Respondents
were asked about their professional roles and demographics at the beginning of the survey. The
study was approved by Institutional Review Boards at Sarah Lawrence College and the NYC
Office of the Chief Medical Examiner.

10

Current Practices in Post-Mortem Cardiogenetic Testing
All data was downloaded from surveymonkey.com. Statistical analysis was conducted
using Microsoft Excel (part of the MS Office Professional Plus 2016 Suite). Responses for all
questions were summarized using the PivotTable function to create frequency distributions and
contingency tables. Responses were coded and collapsed to facilitate interpretation. In particular,
states in the USA were collapsed into the four Census-Bureau-designated regions:
Northwest: CT, ME, MA, NH, RI, VT, NJ, NY, PA
Midwest: IN, IL, MI, OH, WI, IA, KS, MN, MO, NE, ND, SD
South: DE, DC, FL, GA, MD, NC, SC, VA, WV, AL, KY, MS, TN, AR, LA, OK, TX
West: AZ, CO, ID, NM, MT, UT, NV, WY, AK, CA, HI, OR, WA
Results were analyzed using Pearson Chi-square tests and Fisher’s exact tests. Statistical
significance was defined as a p-value equal to or less than 0.05. As sample size was low for
cardiologists and forensic pathologists, their responses were not used as a separate group for
statistical analysis, but were included when considering the total number of responses.
The online survey was sent to approximately 3,090 full members of the National Society
of Genetic Counselors (NSGC); 1000 members of the National Association of Medical
Examiners (NAME); and 900 members of the International Association of Coroners and Medical
Examiners (IACME). Some overlap is possible between the NAME and IACME memberships.
The survey was also distributed to a limited number of cardiologists, with the potential to reach
approximately 120 eligible participants. According to the 2019 NSGC Professional Status
Survey, approximately 279 genetic counselors (GC’s) worked in cardiology, 79 of whom
reported cardiology as their primary area of practice. Given that the response rate on the PSS was
49%, these numbers are conservative estimates for the number of GC’s eligible to take our
survey.
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A total of 99 participants accessed the survey between July 8th, 2019 and December 1,
2019; these included 41 GC’s, 51 ME’s, 4 cardiologists, and 3 forensic pathologists (while there
is overlap in the roles of an ME and a forensic pathologist, we distinguish here those who
described their role as a pathologist and not an ME in this study). Nine individuals indicated that
they have never considered or ordered postmortem genetic testing and skipped a majority of the
questions; these 9 participants were removed. Six other participants completed the full survey but
skipped multiple questions in between; their responses were included for the questions they
answered and omitted for the ones they skipped. In total, the final sample size was 90
individuals, with 37 GC’s, 47 ME’s, 3 cardiologists, and 3 forensic pathologists. Thus, the
genetic counselor response rate was approximately 13.3%, assuming responses came from GC’s
who work either primarily or entirely in cardiology, and 1.2% for all GC’s on NSGC’s student
survey email list. The response rate for medical examiners and cardiologists was 2.5% each.
RESULTS
Respondent Demographics
Of the 37 GC’s, 12 (32.4%) were from the Midwest, 9 (24.3%) were from the West, 8
(21.6%) were from the Northeast, 5 (13.5%) were from the South, 2 (5.4%) were from Canada,
and 1 (2.7%) did not specify their location. Of the 47 ME’s, 14 (29.8%) were from the West, 12
(25.5%) were from the South, 7 (14.9%) were from the Midwest, 7 (14.9%) were from the
Northeast, 3 (6.4%) were from Canada, 2 (4.3%) were from Australia, 1 (2.1%) was from
Singapore, and 1 (2.1%) did not specify their location. For cardiologists, 2 were from the South
(both NC) and 1 was from the Northeast (NY). For forensic pathologists, 2 were from the South
(FL; DC) and 1 was from the West (WA). In general, no significant regional trends or
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discrepancies were identified, but there were several outliers, and these have been identified
when relevant throughout the results section.
Volume of SCD Cases Encountered Annually
Table 1. Volume of SCD cases encountered annually by survey participants in their respective
roles. Table displays categories of numerical ranges, and the number and percentage (n (%)) of
participants that selected each range as capturing their annual SCD case load.
# Cases/Year
0-20
20-40
40-60
60-80
80-100
>100
Skipped
Total
0-20
20-40
Skipped
Total
0-20
20-40
40-60
60-80
>100
Skipped
Total

GC’s
ME’s
Cardiologists
All SCDs
32 (86.5)
11 (23.4)
2 (66.7)
2 (5.4)
13 (27.7)
1 (33.3)
1 (2.7)
5 (10.6)
6 (12.8)
5 (10.6)
1
7 (14.9)
1 (2.7)
37
47
3
Channelopathy-Suspicious SCDs
33 (89.2)
47 (100)
3 (100)
3 (8.1)
1 (2.7)
37
47
3
Cardiomyopathy-Suspicious SCDs
33 (89.2)
39 (83)
2 (66.7)
2 (5.4)
3 (6.4)
1 (2.7)
2 (4.3)
2 (4.3)
1 (2.1)
1 (2.7)
1 (33.3)
37
47
2

Pathologists Total
3 (100)
3

1
48
16
6
6
5
8
90

3 (100)
3

86
3
1
90

3 (100)
3

77
5
3
2
1
2
90

Participants were asked to select a numerical range that captured the number of SCDs
they encounter annually, as well as SCDs suspicious of an arrhythmia, and SCDs suspicious of a
cardiomyopathy. See Table 1 for complete responses. The majority of participants reported
seeing 0-20 annual cases for all types of SCDs. Some significant differences were noted based on
participants’ roles. Collectively, ME’s encountered a significantly higher number of annual SCD
13
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cases than GC’s (p < 0.001). GC’s encountered a significantly higher number of arrhythmiasuspicious SCDs per year than ME’s (p = 0.044).
Laboratory Types and Commonly Used Labs or Organizations for Referral
Laboratory Types
Participants were asked which type or types of lab they used to order testing, and to
specify names of the labs/organizations used if possible. The majority of participants (57/90,
63.3%) reported using a third-party commercial lab. Overall, significantly more GC’s reported
direct ordering from third-party commercial labs, and significantly more ME’s reported referring
cases to other organizations or studies for genetic testing (p < 0.001). Among GC’s, most (32/37,
86.5%) reported using a third-party commercial lab, and other responses were inconsistent. One
GC in Canada who reported using a third-party organization specified that testing is “arranged
through the Ontario coroner system”.
Of 47 ME’s, 7 (14.9%) said they do not order or deal with genetic testing; of these, 1 ME
in Oakland, CA specified that they attempted to send one specimen to Northwestern University,
but were stopped by their administrators as their “office wants the lab to indemnify the office for
liability that results from the testing”. Four ME’s out of the 7 who do no testing specified that
they were financially restrained, or that protocols for genetic testing were cost prohibitive. Only
1 ME (2.13%) at the New York City OCME reported using an in-house lab.
All 3 cardiologists reported using a third-party commercial lab, and 2 of the 3 forensic
pathologists reported the same. The other forensic pathologist reported using an in-house lab.
Complete results are listed in Table 2.
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Table 2. Types of Laboratories Used for Postmortem Genetic Testing in SCD Cases.

Lab Types Used
Third-party commercial
lab
Third-party providers or
research organization
Family is responsible for
arranging third-party
genetic testing
In-house lab
Infrequently/never order
genetic testing
Infrequently/never order
genetic testing for SCDs
Other (unspecified)
Skipped
Total

n (%)
GC’s
32 (86.5)

ME’s
20 (42.6)

Cardiologists

Pathologists

3 (100)

2 (66.7)

Total
57 (63.3)

1 (2.7)

14 (29.8)

-

-

15 (16.7)

-

5 (10.6)

-

-

5 (5.6)

1 (2.7)
-

1 (2.1)
7 (14.9)

-

1 (33.3)
-

3 (3.3)
7 (7.8)

1 (2.7)

-

-

-

1 (1.1)

1 (2.7)
1 (2.7)
37

47

3

3

1 (1.1)
1 (1.1)
90

Frequently Used Third-Party Labs for Postmortem
Genetic Testing in SCD Cases
4

111

1

Invitae
GeneDx
Ambry

12

31

Mayo Clinic
Blueprint Genetics
Prevention Genetics
ARUP

13

Transgenomic/Familion

Figure 1. Pie chart of reported third-party commercial laboratories used for postmortem genetic
testing in SCD cases (includes data from all participants).
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Frequently Used Third-Party Commercial Labs
Participants that reported using third-party commercial labs were asked in an open-ended
question to specify which labs they use most often. The lab named most frequently was Invitae
(31/57, 54.4%). See Figure 1 for a complete list. It is important to note that several of the 57
providers reported use of multiple labs, so there was overlap. For those mentioning multiple labs,
Invitae was most frequently described as the preferred choice.
Third-Party Organizations or Studies to which ME’s Refer SCD Cases for Testing
Of the 14 ME’s that referred families to other organizations, 9 (64.3%) referred them to
university or research groups, and 5 (35.6%) referred them to cardiologists, genetic counselors,
or teams of both. Three university/research groups were specified by the 9 ME’s who refer cases
to them: 4 mentioned the Webster Cardiac Genetics Group at Northwestern University; 3
mentioned the Sudden Death Genomics Laboratory at Mayo Clinic; and 2 mentioned UCSF’s
San Francisco Postmortem Systematic Investigation of SCD clinical research program.
Testing for SCDs Suspicious of Underlying Channelopathy and Cardiomyopathy
Participants were asked about their practice and preferences regarding the ordering of
genetic testing for channelopathy-suspicious and cardiomyopathy-suspicious SCDs with 4
multiple choice questions. See Table 3 for a comprehensive list of questions and responses, with
comparisons of test ordering practice by specialty. An open-ended comment box was included
for respondents to provide further explanation if they reported not ordering genetic testing.
Choosing to Test for Channelopathy-Suspicious SCDs
When asked if they would order genetic testing for channelopathy-suspicious SCDs, the
majority of participants responded Yes (75/90, 83.3%). Significantly more GC’s responded Yes
than ME’s (p < 0.001). Fourteen (29.8%) ME’s responded No; all cited financial constraints by
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the state or their workplace as the reason. A disproportionately higher number of ME’s who do
not order testing were from the South; Southern ME’s were 43% (6/14) of the “do not order”
group, but only 25% (12/47) of total ME respondents.
Types of Genetic Tests Used for Channelopathy-Suspicious SCDs
Of the participants who said that they ordered testing for channelopathy-suspicious
SCDs, the majority (54/75, 72%) selected “arrhythmia panel with both cardiomyopathies and
channelopathies.” Of respondents who selected “channelopathy panel” or said testing is casedependent, most were ME’s. One ME and one forensic pathologist selected “whole exome
sequencing” for both channelopathy and cardiomyopathy-suspicious SCDs; neither commented
on the circumstances or motivations for doing so.
Choosing to Test for Cardiomyopathy-Suspicious SCDs
When asked if they would order genetic testing for cardiomyopathy-suspicious SCDs, the
majority of participants responded Yes (71/90, 78.9%). Significantly more GC’s responded Yes
than ME’s (p < 0.001). Eighteen (38.2%) ME’s responded No; of these, 9 (50%) cited financial
constraints or lack of funds as the reason; 4 (22.2%) stated the testing is unnecessary as
cardiomyopathy can be distinguished morphologically (some added that they would test only if
morphological anomalies were absent or borderline); 4 (22.2%) stated that they don’t test
because cases are referred elsewhere (to studies or genetics teams); 1 (5.6%) stated they don’t
order testing unless requested to do so by the family.
As with channelopathy-suspicious SCDs, a disproportionate number of ME’s who don’t
order testing for cardiomyopathy-suspicious SCDs were located in the South; Southern ME’s
were 33% (6/18) of the “do not order” group, but only 25% (12/47) of all ME respondents.
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Table 3. Respondents’ practice and preferences regarding the ordering of genetic testing for
SCDs suspicious of either channelopathy or cardiomyopathy. Percentages for specific tests
ordered are calculated out of the total number of participants in each role who responded Yes to
testing (for example, 36 GC’s responded Yes for testing; 3 reported using channelopathy panels;
thus, percentage of GC’s ordering channelopathy panels = 3/36 = 8.3%).
n (%)
GC’s

ME’s

Cardiologists Pathologists Total

Do you/would you order genetic testing for channelopathy-suspicious SCDs?
Yes

36 (97.3)

33 (70.2)

3 (100)

3 (100)

75 (83.3)

No

0 (0)

14 (29.8)

0 (0)

0 (0)

14 (15.6)

Skipped

1 (2.7)

0 (0)

0 (0)

0 (0)

1 (1.1)

Total (n)

37

47

3

3

90

What specific test do you order for channelopathy-suspicious SCDs?
Channelopathy panel

3 (8.3)

6 (18.2)

0 (0)

1 (33.3)

10 (13.3)

Arrhythmia panel with
both cardiomyopathies
and channelopathies

30 (83.3)

21 (63.6)

2 (66.7)

1 (33.3)

54 (72)

Whole exome sequencing 0 (0)

1 (3)

0 (0)

1 (33.3)

2 (2.7)

Varies/depends on case

5 (15.2)

1 (33.3)

0 (0)

9 (12)

3 (8.33)

Total (n)
36
33
3
3
Do you/would you order genetic testing for cardiomyopathy-suspicious SCDs?

75

Yes

37 (100)

28 (59.6)

3 (100)

3 (100)

71 (78.9)

No

0 (0)

18 (38.3)

0 (0)

0 (0)

18 (20)

Skipped
Total (n)

0 (0)
37

1 (2.1)
47

0 (0)
3

0 (0)
3

1 (1.1)
90

What specific test do you order for cardiomyopathy-suspicious SCDs?
Channelopathy panel

0 (0)

2 (7.1)

0 (0)

0 (0)

2 (2.8)

Cardiomyopathy panel

17 (46)

3 (10.7)

1 (33.3)

1 (33.3)

22 (31)

Arrhythmia panel with
both cardiomyopathies
and channelopathies

17 (46)

18 (64.3)

1 (33.3)

1 (33.3)

37 (52.1)

Whole exome sequencing 0 (0)

1 (3.6)

0 (0)

1 (33.3)

2 (2.8)

Varies/depends on case

3 (8)

4 (14.3)

1 (33.3)

0 (0)

8 (11.3)

Total (n)

37

28

3

3

71
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Types of Genetic Tests Used for Cardiomyopathy-Suspicious SCDs
Of the participants who said that they did order testing for cardiomyopathy-suspicious
SCDs, the majority (37/71, 52.1%) selected “arrhythmia panel with both cardiomyopathies and
channelopathies.” Of the 22 participants who selected “cardiomyopathy panel”, GC’s
significantly outnumbered ME’s (p = 0.007).
Other Indications for Genetic Testing on the Deceased
Participants were asked in an open-ended question to specify any other reasons for which
they would consider postmortem genetic testing. Of 90 participants, 63 (70%) responded to this
question, some of whom provided multiple other indications. All responses were grouped and
coded into 11 categories based on concerns with similar themes. For each response, all
applicable categories were given a count. See Figure 2 for all categories and the number of
responses that fell into each.

Other Indications for Genetic Testing On the Deceased
State research
Fetal demise
Family interest
Banked DNA
Metabolic disease
Any suspected genetic disorder
Aortopathy
Any SUD
Other SCD prediposing disorders
Family history
Young age
0
GCs

5

10

MEs

Cardiologists

15

20

25

Pathologists

Figure 2. Horizontal stacked bar graph showing other indications for genetic testing of the
deceased as reported by respondents, with their roles distinguished by color. The category “Other
SCD predisposing disorders” includes SUDEP, SIDS, SCAD, RASopathies, congenital heart
diseases, coagulopathies, seizure disorders, and early dementia.
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Genetic Testing of At-Risk Family Members Absent Information on Genetic Status of Deceased
Participants were asked, “Do you order genetic testing on at-risk family members when
you do not have information on the genetic status of the deceased?”. Of 37 GC’s, 20 (54.1%)
selected No and 17 (45.9%) selected Yes. Three (17.7%) of the 17 GC’s who responded Yes
specified that they would provide extensive genetic counseling before testing unaffected family
members and would ideally want the relatives to receive cardiac screening first to identify
symptomatic individuals. Of the 20 GC’s who responded No, 8 (40%) specified that they only
recommend cardiac screening and not genetic testing, and would consider testing in very rare
circumstances of strongly symptomatic individuals or extreme family histories. One such GC
wrote, “Have only ordered on asymptomatic fam members of a deceased once. This was an
extreme family history and no living relatives. We got a lot of VUSs. Was unfortunately
uninformative.” With regards to the type of tests ordered on family members by GC’s, 6/17 GC’s
checked “channelopathy panel”, 6/17 GC’s checked “cardiomyopathy panel”, 15/17 GC’s
checked “arrhythmia channel with both cardiomyopathies and channelopathies”, 1 checked
“whole exome sequencing”, and 2 checked “other” but did not specify.
Of 47 ME’s, 40 (85.1%) responded that they would not order genetic testing on family
members when genetic status of the deceased is unknown, 4 (8.5%) ME’s responded that they
would, and 3 (6.4%) skipped the question. Most of the ME’s who responded No specified that
ordering such testing is not part of their job; 5 ME’s specified that they refer families to genetic
counselors or cardiologists if a genetic etiology is suspected. With regards to the type of tests
ordered on family members by ME’s, 2/4 ME’s indicated “channelopathy panel”, 2/4 ME’s
indicated “arrhythmia channel with both cardiomyopathies and channelopathies”, 1 indicated
“whole exome sequencing”, and 2 indicated “other”, one of whom indicated prodrome-specific
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testing (for symptomatic family members who already undergo cardiac screening), and the other
indicated following a physician’s recommendations.
Among cardiologists, 2/3 responded Yes to testing for family members, 1/3 responded
No. Both cardiologists who responded Yes indicated using the “arrhythmia panel with both
cardiomyopathies and channelopathies”; one of them also indicated “whole exome sequencing”.
All 3 forensic pathologists responded No, stating that testing relatives is not part of their job.
Contributing Factors for Postmortem Genetic Testing
Participants were asked to choose which factors contribute to whether or not postmortem
genetic testing is completed (they could select as many factors as they desired). Six potential
factors were listed, along with an “Other” option. When asked which factor is the most
important, “financial” was chosen by the greatest number of participants (38/90, 42.2%).
However, the most important factor for GC’s alone was “sample type/amount”, while “financial”
came second (Table 4, Figure 3). The number of ME’s who selected “financial” as the most
important factor was significantly greater than the number of GC’s who did so (p = 0.009).
Significantly more GC’s selected “sample storage/retention” as a determining factor of
postmortem genetic testing than ME’s (p < 0.001). See Table 4 for all responses.
Financial Responsibility of Genetic Testing for the Deceased
Participants were asked “Who is responsible for the cost of genetic testing?” with regards
to testing the deceased. Approximately a third of participants (31/90, 34.4%) said that families
paid out-of-pocket; 26 (28.9%) said the ME office paid; 10 (11.1%) said it was highly variable
and depended on each case; 5 (5.6% ) said the cost was covered by research funds/grants; 2
(2.2%) selected “decedent’s insurance”; 2 (2.2%) selected “family member’s insurance”; 4
(4.4%) said they are unsure and don’t know; 3 (3.3%) skipped the question. (continued page 21)

21

Current Practices in Post-Mortem Cardiogenetic Testing
Table 4. Obstacles to Postmortem Genetic Testing
Potential Contributing
Factors

GC

ME

Cardiologist

Pathologist

Total

Financial

30

33

3

2

68

Sample type/amount

34

21

1

2

58

Sample storage/retention

30

8

-

-

38

Shipping Process

7

4

-

-

11

Turnaround time

2

9

1

-

12

Informed consent

14

9

1

-

24

“Index of suspicion”

2

4

-

-

6

Family involvement

5

3

-

-

8

ME Office liability

-

1

-

-

1

ME knowledge

2

-

-

-

2

Difficulty of whole process

1

-

-

-

1

Most Important Obstacle to Postmortem Genetic Testing
Difficulty
ME Knowledge
ME Office Liability
Family's involvement
Index of suspicion
Informed consent
Turnaround time
Sample storage/retention
Sample type/amount
Financial
Skipped
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Forensic Pathologist

Figure 3. Horizontal stacked bar graph showing the number of participants in each role and their
response for which contributing factor is most important to whether or not postmortem genetic
testing is completed.
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The remaining 7 (7.8%) participants reported that costs were covered by hospitals, attorneys, or
government healthcare (these respondents were ME’s or GC’s in Australia or Canada). When
correlating responses with participants’ roles, there was a significant difference between GC and
ME responses (p < 0.001); the majority of GC’s reported families paying out-of-pocket for
postmortem genetic testing (24/37, 64.8%), while ME’s most commonly reported costs being the
Medical Examiner Office’s responsibility (23/47, 48.9%) (See Figure 4). No significant regional
variation was detected.

Financial Responsibility for Postmortem Genetic Testing
Unsure/don't know
Highly variable
Attorney
Government
Research funds/grants
Hospital
Family out of pocket
Insurance (family member)
Insurance (decedent)
ME office
0

5

10

15

20

25

30

35

Number of Responses
GC

ME

Cardio

FP

Figure 4. Horizontal stacked bar graph showing the number of participants in each role and their
response for which parties are responsible, in their experience, for the cost of postmortem genetic
testing. GC’s and ME’s were significantly different in their responses (p < 0.001).
Turnaround Time (TAT) for Postmortem Genetic Testing
Participants were asked, “When post-mortem genetic testing is ordered, what is the
average turnaround time in months (from autopsy to disclosing genetic results to families)?”
Responses were grouped into categories of 3-month increments. The largest group of participants
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(32/90, 35.6%), regardless of whether they were GC’s (13/37, 35.1%) or ME’s (16/47, 34%),
reported the average TAT for postmortem genetic testing as 1-3 months.
Referral to Direct-to-Consumer/Consumer-Initiated Testing Options
Participants were asked, “For family members who don't qualify for/can't afford clinical
genetic testing, do you refer them to DTC (direct-to-consumer) genetic testing options?”. The
majority of participants (69/90, 76.7%) said they would not. Of 37 GC’s, 2 (5.4%) said they
would offer DTC options for testing the deceased. One of them specified: “I know families that
have paid for genome trios through Perkin Elmer, which I am comfortable with”. The other GC
said they offer Color or testing through Invitae’s DETECT program. One GC said they do not
currently offer DTC options, but will offer Color or Invitae in the future. Of 47 ME’s, 5 (10.6%)
said they offer DTC options for testing family members. Two ME’s and 2 of the 3 forensic
pathologists said they would offer DTC options for testing both the deceased and their relatives.
Pre-Test Counseling for Postmortem Genetic Testing
Participants were asked, “Before the deceased is tested, who provides pre-test counseling
to the deceased's family? Select all that apply.” Six participants (6/90) skipped this question. Of
all the options, “Genetics” was reported by the most participants in total (47/90), followed by
“No pre-test counseling is provided” (25/90), “Cardiologists” (22/90), “Medical examiners”
(14/90) and “PCP (primary care practitioner)” (9/90). See Figure 5 for the full distribution of
responses. There were significant differences between GC’s’ and ME’s’ responses (p < 0.001);
more ME’s reported that no pre-test counseling is provided.
Points Discussed During Pre-Test Counseling
Those participants who did pre-test counseling were asked to select which topics were
covered. Five potential topics were listed, along with an “Other” option. Participants could select
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all that applied. The majority of participants who responded were GC’s (36/37, 97.3%), as many
ME’s (33/47, 70.2%) and all three forensic pathologists were not involved with pre-test
counseling. “Potential results” was the most selected topic by both GC’s and the ME’s who
responded. Two GC’s reported discussing testing logistics and coverage; one ME reported
discussion of referral to PCP for follow-up. Table 5 lists the topics selected and displays the
number of respondents who reported each topic as being included in pre-test counseling.

Providers of Pre-Test Counseling for Postmortem Genetic Testing
in SCD Cases
No pre-test counseling provided
Research Protocol
Consultant

GC

Medical Examiners

ME

Cardiologists

Cardiologist

Genetics
PCP

Forensic pathologists
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30

40

50

Number of Participants

Figure 5. Horizontal stacked bar graph showing the number of participants that reported which
types of providers are in charge of providing pre-test counseling to families for postmortem
genetic testing of SCD cases.
Table 5. Topics Covered in Pre-Test Counseling for Postmortem Genetic Testing in SCDs.
Table shows the number of participants (by role) who indicated coverage for each topic.
Topics Covered

GC’s

ME’s

Cardiologists

Total

Potential Results

30

8

2

40

Management

26

5

1

32

Insurance coverage

18

2

2

22

Family Planning

26

2

2

30

Educational Resources

20

4

-

24

Referral

-

1

-

1

Logistics

2

-

-

2
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Post-Test Counseling for Postmortem Genetic Testing
Participants were asked, “After the deceased is tested, who provides post-test counseling
to the deceased's family? Select all that apply.” Seven participants (7/90) skipped this question.
Of all the options, “Genetics” was reported by the most participants in total (61/90), followed by
“Cardiologists” (28/90), “Medical examiners” (16/90), and “PCP (primary care practitioner)”
(11/90). Six participants (5 ME’s, 1 forensic pathologist) reported that no post-test counseling is
provided. See Figure 6 for the full distribution of responses.
Points Discussed During Post-Test Counseling
Participants who do post-test counseling were asked to select which topics were covered.
Five potential topics were listed, along with an “Other” option. Participants could select all that
applied. The majority of participants who responded were GC’s, as many ME’s and 2/3 forensic
pathologists were not involved with post-test counseling and wrote “not applicable”. “Actual
results” was the most selected topic by both GC’s and ME’s. Four ME’s reported referring
families to other providers, two of whom mentioned referral to PCPs, and two referred to genetic
counselors/geneticists. Table 6 shows the number of participants who indicated that each topic is
covered in post-test counseling.
Table 6. Topics Covered in Post-Test Counseling for Postmortem Genetic Testing in SCDs.
Table shows the number of participants (by role) who indicated coverage for each topic.
Topics Covered
Actual results
Management course
Insurance coverage
Family planning
Educational
resources
Referral to others

GC’s
32
30
22
29
27

ME’s
14
3
1
10

Cardiologists
2
1
1
1
1

Pathologists
1
-

Total
49
34
23
31
38

-

4

-

-

4

26

Current Practices in Post-Mortem Cardiogenetic Testing

Providers of Post-Test Counseling for Postmortem Genetic
Testing in SCD Cases
No post-test counseling provided
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Figure 6. Horizontal stacked bar graph showing the number of participants that reported which
types of providers are in charge of providing post-test counseling to families for postmortem
genetic testing of SCD cases.
Factors for Denying Postmortem Genetic Testing When Cost is not a Barrier
Participants were asked, “In your experience, which of the following factors has
prompted a family to deny post-mortem testing when the cost of testing is not a barrier? Check
all that apply.” They could choose from “grief”, “misinformation”, “miscommunication”, and
“cultural/religious reasons”. Thirty-one respondents (31/90, 34.4%)—8 GC’s and 23 ME’s—
skipped this question. For those who responded, “Grief” was the most selected reason (34/59),
followed by “misinformation” (28/59), “cultural/religious reasons” (21/59), and
“miscommunication” (18/59). As a group, ME’s were more likely to choose “misinformation”
(12/24, 50%) than “grief” (8/24, 33.3%).
Insurance Coverage of Genetic Testing for the Deceased and for Living Family Members
Participants were asked about their experience with insurance coverage of postmortem
testing for the deceased (62/90, 68.9% responded). Responses were coded into 5 categories; see
Figure 9 for all responses. Among those that said they often see insurance cover costs of testing,
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two ME’s indicated that the UCSF genetic counselors they refer families to are “good at getting
insurance companies to pay” and one cardiologist said “With proper documentation and medical
records, the majority of cases are covered.” One notable regional trend was that Southern
practitioners made up 55% (11/20) of “never” responses, but only 23% (21/90) of all
participants. Participants were also asked about insurance coverage for genetic testing of family
members when test results are not available for the deceased proband (67/90, 74.4% responded).
See Figure 7 for all responses. No regional trends were noted.
Insurance Coverage for Family Members

Number of Participants
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Figure 7. Frequency of insurance coverage of postmortem genetic testing for the deceased
(n=62), and for family members when genetic status of the deceased is unknown (n=67).
DISCUSSION
This study’s main focus was to gain insight into the perspective of healthcare
professionals (medical examiners, genetic counselors, and cardiologists) on postmortem genetic
testing, particularly with regards to SCDs suspicious of underlying channelopathy or
cardiomyopathy. The survey included a series of questions to address the following: what
specific medical events necessitate postmortem genetic testing; who is ordering postmortem
testing; what specific tests are being ordered; and how does insurance coverage for postmortem
28

Current Practices in Post-Mortem Cardiogenetic Testing
testing vary by region. The majority of respondents were GC’s and ME’s who either have a
primary role or background in cardiology, and only three cardiologists and three forensic
pathologists completed the survey.
With regard to postmortem genetic testing, our survey suggests that there are differences
in what GC’s and ME’s regard as their role in the process; there are also inconsistencies in
insurance coverage of postmortem genetic testing, none of which appear to be attributable to
regional variation.
Inconsistencies in the Postmortem Genetic Testing Process
The discrepancy between how ME’s approach postmortem genetic testing and how GC’s
approach postmortem genetic testing is significant. In general, all respondents emphasized that
both pre-test and post-test counseling for postmortem genetic testing should be done by genetic
professionals. However, more ME’s than GC’s reported that no pre-test counseling is provided
when postmortem genetic testing is offered. This suggests that the amount of information
available to patients prior to consenting to postmortem genetic testing is inconsistent.
Discrepancies Pertaining to Which Factors Prevent Postmortem Genetic Testing from Happening
One significant discrepancy between the two main groups of respondents was in what
each group identified as the principle contributing factor preventing postmortem genetic testing.
A majority of the ME’s surveyed reported that financial constraints are the main reason why
postmortem genetic testing is not facilitated, and that the financial responsibility for such testing
falls onto the medical examiner’s office rather than the family or insurance companies. On the
other hand, GC’s were significantly more likely to select “sample type/amount” as the main
obstacle to postmortem genetic testing (p<0.001). It is unclear why this difference in GC and ME
perspective exists. Possible explanations include: ME’s lack a comprehensive understanding of
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sample type/amount requirements for postmortem genetic testing during the autopsy and don’t
retain appropriate samples; ME’s are removed from follow-up and are unaware if testing is
actually achieved; financial constraints behave as the primary obstacle and influence adequate
sample collection; and a general lack of communication exists between GC’s and ME’s.
Our results are inconsistent regarding whether or not insurance companies will cover
postmortem genetic testing on SCD cases. Responses indicate that some families are paying for
postmortem genetic testing, and some have insurance cover the testing, while other cases are
covered by the ME’s office. Another potential area of focus for future studies is influenced by
GC involvement; it is possible that certain GC activities, such as writing letters of medical
necessity, play a crucial role in securing insurance coverage, making it less of impediment for
GC’s. Overall, inconsistency when it comes to who is financially responsible and what insurance
will cover raise a red flag, indicating that cost may impact availability of testing in many cases.
Alternative Postmortem Genetic Testing Options Discussed by Healthcare Professionals
Respondents proposed the following methods to help families obtain postmortem genetic testing:
•

Providing proper documentation and medical records as evidence to insurance companies
as to why postmortem genetic testing is necessary

•

Direct-to-consumer/Consumer Initiated testing (Color or Invitae) for families with
financial constraints

•

Enrolling in clinical research programs offered at specific institutions (Webster Cardiac
Genetics Group at Northwestern University, San Francisco Postmortem Systematic
Investigation of Sudden Cardiac Death (POST SCD) clinical research program, and
Sudden Death Genomics Laboratory at Mayo Clinic)

•

Selecting a lab that is cost effective (e.g., Invitae verse GeneDx)

•

Molecular autopsy labs within medical examiners’ offices
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Direct-to-consumer/consumer-initiated testing (DTC/CIT) allows families interested in
postmortem genetic testing on to have it done at a more affordable price. About 5% of GC’s said
they would offer DTC/CIT options for testing the deceased. About 11% of ME’s, 5 (10.6%) said
they offer DTC/CIT options for testing family members. Two ME’s and 2 of the 3 forensic
pathologists said they would offer DTC/CIT options for testing both the deceased and their
relatives.
Studies mentioned by individual respondents vary in terms of inclusion criteria in terms
of what they require to determine cause of death and other eligibility restrictions. Some are open
to referrals from physicians nationwide, while others are regional programs. The San Francisco
Postmortem Systematic Investigation of Sudden Cardiac Death (POST SCD) clinical research
program is unique in that it is a partnership between cardiac electrophysiology specialists and the
County Medical Examiner. The cases eligible for this program are only out-of-hospital sudden
death within the County of San Francisco meeting WHO criteria.
Selecting specific lab companies can help reduce cost to families as well. One respondent
cited an Invitae program called Detect, which provides free-of-charge genetic testing for
conditions in which testing is underutilized and can improve diagnosis and treatment. These
conditions include cardiomyopathy and arrhythmia, as well as lysosome storage diseases and
amyloidosis in the Cardiology category. In addition to testing, the Detect programs offer
participants post-test genetic counseling to help them understand their test results and make more
informed decisions about their health. Some programs also offer follow-up testing to family
members of patients with genetic variants associated with disease to better understand their
disease risks. In general, Invitae covers family follow-up testing for patients with a relative who
was tested at Invitae (within 90 days of order) and was found to have a pathogenic/likely
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pathogenic variant or a variant of uncertain significance (VUS resolution at no additional
charge). Therefore, if the family has to pay out of pocket for postmortem genetic testing, the
follow-up testing for family members (if ordered within the specific time frame) is covered.
Unlike Invitae, GeneDx states that once a pathogenic or likely pathogenic variant is identified in
the proband, targeted testing of family members is recommended and can be performed at a
reduced cost of $99 USD for those meeting certain criteria (as of March 2020).
Most ME offices around the world lack the technology and finances to routinely perform
molecular testing on every autopsy-negative natural death case (Sampson and Tang, 2017). In
New York City, the Office of Chief Medical Examiner has its own Molecular Genetics
Laboratory that started in 2003, which is the only such laboratory based in a medical examiner’s
office nationwide. The laboratory provides postmortem molecular diagnostic testing to search for
gene changes that explain sudden deaths, and to alert surviving family members. There are no
charges for this service to the family.
Implications for Practice
In general, the results showed that there are inconsistencies in how ME’s function in
postmortem genetic testing. For example, 14.9% of the ME’s emphasized that they do not order
or deal with genetic testing, 29.8% refer families to a third-party organization for test-related
decision-making, and 42.6% facilitate postmortem genetic testing themselves. It may be that
ME’s would benefit from continuing education or guidelines to establish a baseline
understanding of their role in postmortem genetic testing. This, potentially, could facilitate
adherence to a uniform testing and counseling protocol for families affected by SCD
Another subject for discussion that could be evaluated is whether or not medical
examiners’ offices should incorporate GC’s into their practice to help ensure that all families
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who are thinking of undergoing postmortem genetic testing receive appropriate counseling prior
to testing. Again, this might help establish a uniform level of care for all families who have
experienced the loss of a family member due to SCD. More GC’s employed by medical
examiner offices might also improve communication and reduce the likelihood of an inadequate
sample type/amount, which GC’s in this study had pointed to as a primary obstacle to
postmortem genetic testing.
In Middleton et al (2013), they discuss the collaborative efforts of genetic counselors and
NAME to improve postmortem genetic testing protocols. The authors concluded, “medical
examiners not only have the responsibility of determining cause and manner of death, but also
function as stewards of public health promotion and monitoring”. The results from this study
indicated that not all ME’s are incorporating best practices for pre- or post-test counseling in the
postmortem. In Bagnall et al. (2020), they emphasize that “the molecular autopsy is not without
challenges” and “can be time-intensive”. These specific types of cases make up a small
percentage of the total caseload brought to an ME’s attention, since they are also highly involved
in cases of homicide, accidents, other natural deaths, etc. Therefore, this makes having a
multidisciplinary team approach (medical examiners, cardiologists, genetic counselors and
geneticists) very valuable when selecting the optimal panel of genes and interpretations of
genetic results. Efforts to promote uniformity in how ME’s and GC’s work together may benefit
families in need of postmortem genetic testing.
With regards to cost, an appeal to insurance companies may help to generate
improvements in insurance companies’ policies so that a fair and predictable process is available
for families considering postmortem genetic testing. While research studies and payment through
ME’s offices remain an option for many families today, they have restrictions and cannot be
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relied on to provide access on a consistent basis. As has been seen, labs may also be willing to
absorb some cost if necessary.
Research Recommendations
Further research is needed to understand the role of ME’s in postmortem genetic testing
and to what extent that role necessitates additional training. The benefits and limitations of the
following ideas should be explored: (1) Having GC’s employed by ME’s offices or (2) ME
offices having universal referral programs where appropriate samples are sent to Genetics for
any SCD case, and all genetic information pertinent to the cause of death is communicated back.
It should also be evaluated whether or not each idea: reduces misinformation and
miscommunication; improves TAT; increases the number of cases that get pre-test and post-test
counseling; and alters the percentage of families that agree to postmortem genetic testing.
Our study showed several regional trends, with ME’s in the Southern region of the U.S.
more likely to report financial constraints affecting the availability of testing and a majority of
southern healthcare professionals reporting that postmortem genetic testing to is “never” covered
by insurance companies. Future studies might explore if these differences can be replicated, and
investigate possible factors creating regional differences in policy or practice
Study Limitations
The survey was distributed through listservs as well as through personal contacts; there is
potential for ascertainment bias, as those who click and proceed to take the survey are most
interested in the topic. Our study originally aimed to compare responses between GC’s, ME’s,
and cardiologists, but due to unsuccessful attempts at recruiting cardiologist respondents, we
were unable to conduct such comparisons. Another limitation is the low sample size for each
state, leading us to collapse respondents by region and possibly missing certain location-based

34

Current Practices in Post-Mortem Cardiogenetic Testing
trends or patterns. Also, there was potential for human error when coding and categorizing
qualitative responses. The last question in the survey was open-ended and phrased as such: “In
what situations will insurance companies cover cascade genetic testing for family members if the
deceased has not been tested?”. This question involved incorrect usage of the term “cascade
testing”, as cascade testing refers specifically to testing of family members after a genetic variant
has been discovered in the proband. This error could have potentially led to misinterpretation and
inaccurate responses. Future studies exploring the same topic should take additional care with
question design. A better alternative would have been similarly phrased with the word “cascade”
omitted.
Conclusion
In conclusion, while this study identified some cost-reductive and cost-free methods of
how to approach postmortem genetic testing, it also highlighted inconsistencies in how
postmortem genetic testing is practiced and paid for, and the roles played by healthcare
professionals. More effort is needed to establish a uniform understanding among healthcare
professionals and insurance companies of the importance of postmortem genetic testing and the
necessary components of pre-test and post-test counseling, as well as coverage of postmortem
genetic testing, and the relevance of postmortem genetic testing in management of family
members with a family history of SCD. This topic requires further research and interdisciplinary
consideration to help establish guidelines and protocols that healthcare professionals can follow
in order to provide uniform care to patients.
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